Influenza vaccines

A flu vaccine, influenza technology, applied in vaccines, multivalent vaccines, immunoglobulins, etc., can solve problems such as damage to antigenic proteins

Active Publication Date: 2011-08-31
GAMMA VACCINES
View PDF30 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, chemically inactivated influenza vaccine formulations require the use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza vaccines
  • Influenza vaccines
  • Influenza vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] Example 1: Intravenous administration of BALB / c mice with gamma-irradiated influenza A virus inoculation

[0240] (i) Materials and methods

[0241] animal

[0242] BALB / c mice of the same sex and in a similar age group (8-12 weeks old) were used in each experiment.

[0243] virus and immunity

[0244] As described by Yap et al., 1977, "Cytotoxic T cells specific for influenza virus-infected target cells", Immunology, 32: 151, for influenza virus strains A / WSN (H1N1), A / JAP (H2N2) and A / PC(H3N2) for incubation and titration. Virus titers were expressed as hemagglutination units (HAU). By exposing crude allantoic fluid to Co 60 Source 1.26X 10 6 rads (12.6 KGy) (60 h exposure at 350 rads / min), or by exposing dialyzed infectious allantoic fluid to UV radiation (320 μW / cm 2 ) for 10 minutes to inactivate the A / JAP influenza virus. Exposure to gamma or UV irradiation for these periods completely abolished infectivity as tested in embryonated eggs. By a single ...

Embodiment 2

[0274] Example 2: Intravenous inoculation of gamma-irradiated influenza A strains A / WSN [H1N1], A / PR8 [H1N1], A / JAP [H2N2] and A / PC [H3 / N2]

[0275] (i) Materials and methods

[0276] animals and viruses

[0277] Stocks of influenza A virus (strain A / WSN, A / Pr8[H1N1]; A / JAP[H2N2]; A / PC[H3N2]) were prepared in 10-day-old embryonated eggs. Viral stocks were prepared from allantoic fluid and stored in aliquots at -70°C. Initially, BALB / c and C57B1 / 6 mice were infected intranasally and the severity of influenza virus infection was evaluated in terms of mortality, body weight loss, lung histology and lung infiltration.

[0278] Gamma-irradiation of influenza virus strains

[0279] Gamma-ray dose-response studies of frozen and room temperature-maintained virus stocks were performed at NSTO / Lucas Heights / NSW to determine conditions that yielded inactivated virus preparations with optimal immunogenicity. 5x10 5 An irradiation dose of rads (5 KGy) was sufficient to induce inactiva...

Embodiment 3

[0302] Example 3: Intranasal vaccination with gamma-irradiated influenza A virus protects against H5N1 (avian influenza).

[0303] (i) Materials and methods

[0304] animal

[0305] Ten-week-old BALB / c mice were used in this experiment.

[0306] Virus

[0307] Virus stocks of two influenza A strains (A / PR8[H1N1] and A / PC[H3N2]) were grown in embryonated chicken eggs and purified by temperature-dependent adsorption to chicken erythrocytes, and passage through Madin Darby canine kidney (MDCK) cells were assessed for viral titers using standard plaque assays and titers were expressed as pfu / mls.

[0308] Gamma-irradiation of influenza strains

[0309] Expose purified stock to 1x10 6 rad (10 kGy) gamma-rays (ANSTO, Lucas Height, Australia) as described in Example 2 above. Residual virus infectivity in irradiated stocks was detected by using embryonated chicken eggs. Viral stocks are inactivated, but phantom hemagglutination activity is maintained after irradiation.

[0310] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sizeaaaaaaaaaa
Titeraaaaaaaaaa
Login to view more

Abstract

The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus.

Description

field of invention [0001] The present invention relates to compositions and methods for preventing and treating influenza virus infection. More specifically, the present invention relates to vaccine compositions and methods for eliciting cross-reactive immunity to influenza viruses. Background of the invention [0002] Influenza is a highly contagious disease caused by respiratory infection of influenza virus. It can lead to potentially life-threatening complications, especially in infants and the elderly. [0003] Protection against reinfection by homologous viruses is primarily mediated by neutralizing antibodies, but recovery from influenza virus infection requires a cytotoxic CD8+ T (Tc) cell response. Current vaccines against influenza viruses are mainly inactivated whole virus or subunit preparations in which the infectivity of the virus is inactivated by chemical treatment. These vaccines almost all work by inducing neutralizing antibodies targeting viral surface g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/145A61P31/16A61K39/00
CPCA61K39/145A61K2039/5252C12N2760/16134A61K2039/543A61K2039/545A61K2039/58A61K2039/70C12N2760/16234C07K16/1018C12N7/00C12N2760/16161C12N2760/16163A61K39/12A61P31/16A61P37/04C12N2760/16171
Inventor 穆罕默德·阿尔沙利费阿诺·穆立巴彻尔
Owner GAMMA VACCINES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap